Gilead Sciences, Inc. $GILD Stock Holdings Increased by Glenview Trust Co

Glenview Trust Co lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 187,726 shares of the biopharmaceutical company’s stock after purchasing an additional 3,868 shares during the quarter. Glenview Trust Co’s holdings in Gilead Sciences were worth $20,838,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $215,000. Sivia Capital Partners LLC lifted its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the period. Crewe Advisors LLC boosted its holdings in shares of Gilead Sciences by 24.3% in the second quarter. Crewe Advisors LLC now owns 726 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 142 shares in the last quarter. Finally, Princeton Global Asset Management LLC increased its stake in shares of Gilead Sciences by 58.2% during the second quarter. Princeton Global Asset Management LLC now owns 791 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 291 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares in the company, valued at $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 288,891 shares of company stock worth $40,303,946 over the last three months. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Oppenheimer boosted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Morgan Stanley raised their target price on Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Scotiabank boosted their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. Finally, Mizuho upped their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Twenty-three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Stock Up 2.1%

Shares of Gilead Sciences stock opened at $154.98 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The firm has a market capitalization of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 2.06 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The stock’s fifty day moving average is $130.94 and its 200-day moving average is $122.68.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is 46.68%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.